CoChat

Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity

Open access

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

High Resolution Image Download MS PowerPoint Slide Neuronal Kv7 channels represent important pharmacological targets for hyperexcitability disorders including epilepsy. Retigabine is the prototype Kv7 activator clinically approved for seizure treatment; however, severe side effects associated with long-term use have led to its market discontinuation. Building upon the recently described cryoEM structure of Kv7.2 complexed with retigabine and on previous structure–activity relationship studies, a small library of retigabine analogues has been designed, synthesized, and characterized for their Kv7 opening ability using both fluorescence- and electrophysiology-based assays. Among all tested compounds, 60 emerged as a potent and photochemically stable neuronal Kv7 channel activator. Compared to retigabine, compound 60 displayed a higher brain/plasma distribution ratio, a longer elimination half-life, and more potent and effective anticonvulsant effects in an acute seizure model in mice. Collectively, these data highlight compound 60 as a promising lead compound for the development of novel Kv7 activators for the treatment of hyperexcitability diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.2c00911

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Synthesis of 1,4-Phenylenediamine (2), Benzene-1,2,4-triamines (13−20), 2-(pyrrolidin-1-yl)benzene-1,4-diamine (23), 2-(Piperidin-1-yl)benzene-1,4-diamine (24), N4-Alkylbenzene-1,2,4-triamine (25,26,27), and N-(3,4-Diaminophenyl)acetamide (28) Derivatives
Scheme 1 Synthesis of 1,4-Phenylenediamine (2), Benzene-1,2,4-triamines (13−20), 2-(pyrrolidin-1-yl)benzene-1,4-diamine (23), 2-(Piperidin-1-yl)benzene-1,4-diamine (24), N4-Alkylbenzene-1,2,4-triamine (25,26,27), and N-(3,4-Diaminophenyl)acetamide (28) DerivativesCC BY · PubMed Central
Scheme 2 Synthesis of 3,4-Diaminophenol Derivative 31
Scheme 2 Synthesis of 3,4-Diaminophenol Derivative 31CC BY · PubMed Central
Scheme 3 Synthesis of Benzene-1,2,4-triamine Derivatives 41–43, 47, 51, 52, and 57
Scheme 3 Synthesis of Benzene-1,2,4-triamine Derivatives 41–43, 47, 51, 52, and 57CC BY · PubMed Central
Scheme 4 Synthesis of N-((2-Amino-3-fluoro-4-(benzyl)amino)phenyl)amide (59 and 60), N-(2-Amino-4-(4-(trifluoromethyl)phenethyl)phenyl)amide (67 and 68) Derivatives, and 2-Amino-N-hexyl-4-((4-(trifluoromethyl)benzyl)amino)benzamide (71)
Scheme 4 Synthesis of N-((2-Amino-3-fluoro-4-(benzyl)amino)phenyl)amide (59 and 60), N-(2-Amino-4-(4-(trifluoromethyl)phenethyl)phenyl)amide (67 and 68) Derivatives, and 2-Amino-N-hexyl-4-((4-(trifluoromethyl)benzyl)amino)benzamide (71)CC BY · PubMed Central
Figure 1 Functional characterization of a first series of retigabine derivatives (compounds 13–20, 71, 2, 23, 24, 41–43, 47, 51, 52, 57). (A) Retigabine compounds 23a and 24a structures with the three different areas investigated by structure-based approach. Highlighted: area 1 in blue, area 2 in orange, and area 3 in red. (B) Retigabine binding pocket in Kv7.2 channels. The two Kv7.2 subunits shown are colored in cyan and salmon. Bound conformations of 23a (yellow) and 24a (green) are shown in thin solid sticks. For each ligand, three bound conformations (sampled at 0, 60, and 120 ns from 120 ns-long MD simulations of the ligand/Kv7.2 complex) are shown. Experimentally solved bound conformation of retigabine (PDB ID: 7CR2) is shown in magenta thick transparent sticks. (C) FluxOR fluorescence signals generated in Kv7.2/Kv7.3-transfected cells by the following: vehicle DMSO 0.1% (gray curve), retigabine (RET, purple curves), and retigabine + XE991 co-administrated (black curve). Non-transfected cell (NT) signal is also shown. (D,E) Average value of maximal fluorescence (FMAX/F0; D) and initial slope (E) of the FluxOR fluorescence signal calculated between 5 and 15 s. (F) Dose–response curves of RET (purple) and RL-81 (yellow). Solid lines represent fits of the experimental data to the four parameter logistic equation used to estimate EC50 values. (G) Average FluxOR fluorescence signals obtained in Kv7.2/Kv7.3-transfected cells upon exposure to the synthesized compounds exploring the chemical space at area 1 (blue bars), area 2 (orange bars), and area 3 (red bars) at a concentration of 10 μM in comparison with retigabine (purple bar). * and # indicate values significantly different (p < 0.05) from respective controls.
Figure 1 Functional characterization of a first series of retigabine derivatives (compounds 13–20, 71, 2, 23, 24, 41–43, 47, 51, 52, 57). (A) Retigabine compounds 23a and 24a structures with the three different areas investigated by structure-based approach. Highlighted: area 1 in blue, area 2 in orange, and area 3 in red. (B) Retigabine binding pocket in Kv7.2 channels. The two Kv7.2 subunits shown are colored in cyan and salmon. Bound conformations of 23a (yellow) and 24a (green) are shown in thin solid sticks. For each ligand, three bound conformations (sampled at 0, 60, and 120 ns from 120 ns-long MD simulations of the ligand/Kv7.2 complex) are shown. Experimentally solved bound conformation of retigabine (PDB ID: 7CR2) is shown in magenta thick transparent sticks. (C) FluxOR fluorescence signals generated in Kv7.2/Kv7.3-transfected cells by the following: vehicle DMSO 0.1% (gray curve), retigabine (RET, purple curves), and retigabine + XE991 co-administrated (black curve). Non-transfected cell (NT) signal is also shown. (D,E) Average value of maximal fluorescence (FMAX/F0; D) and initial slope (E) of the FluxOR fluorescence signal calculated between 5 and 15 s. (F) Dose–response curves of RET (purple) and RL-81 (yellow). Solid lines represent fits of the experimental data to the four parameter logistic equation used to estimate EC50 values. (G) Average FluxOR fluorescence signals obtained in Kv7.2/Kv7.3-transfected cells upon exposure to the synthesized compounds exploring the chemical space at area 1 (blue bars), area 2 (orange bars), and area 3 (red bars) at a concentration of 10 μM in comparison with retigabine (purple bar). * and # indicate values significantly different (p < 0.05) from respective controls.CC BY · PubMed Central
Figure 2 Molecular dynamics (MD) simulations of retigabine analogues. (A) Predicted bound conformations of 13 (orange), 14 (green), 17 (pink), 18 (light gray), and 19 (dark gray) at 60 ns of MD simulations are depicted in sticks. (B) Bound conformations of 15 (yellow) and 16 (magenta) at 60 ns of MD simulations are depicted in sticks. (C) Predicted bound conformation of 17 (magenta sticks) at 60 ns of MD simulations. (D) Predicted bound conformations of 23 (yellow sticks) and 24 (magenta sticks). In all panels, the two different Kv7.2 monomers are depicted in sticks and cartoons and colored in cyan and salmon. H-bonds are represented by yellow dashed lines.
Figure 2 Molecular dynamics (MD) simulations of retigabine analogues. (A) Predicted bound conformations of 13 (orange), 14 (green), 17 (pink), 18 (light gray), and 19 (dark gray) at 60 ns of MD simulations are depicted in sticks. (B) Bound conformations of 15 (yellow) and 16 (magenta) at 60 ns of MD simulations are depicted in sticks. (C) Predicted bound conformation of 17 (magenta sticks) at 60 ns of MD simulations. (D) Predicted bound conformations of 23 (yellow sticks) and 24 (magenta sticks). In all panels, the two different Kv7.2 monomers are depicted in sticks and cartoons and colored in cyan and salmon. H-bonds are represented by yellow dashed lines.CC BY · PubMed Central
Figure 3 Functional characterization of a second series of retigabine derivatives with improved photostability (compound 25–28, 31, 59, 60, 67, 68). (A) Proposed mechanism for retigabine photo-oxidation. (B) Average FluxOR fluorescence signals obtained in Kv7.2/Kv7.3-transfected cells upon exposure to the indicated photostable compounds, each used at a concentration of 10 μM in comparison with retigabine (RET 10 μM; purple bar). * indicates values significantly different (p < 0.05) from respective control. (C) HPLC traces of retigabine (RET) and compound 60 at 550 nm after 3 h exposure to UV–visible light.
Figure 3 Functional characterization of a second series of retigabine derivatives with improved photostability (compound 25–28, 31, 59, 60, 67, 68). (A) Proposed mechanism for retigabine photo-oxidation. (B) Average FluxOR fluorescence signals obtained in Kv7.2/Kv7.3-transfected cells upon exposure to the indicated photostable compounds, each used at a concentration of 10 μM in comparison with retigabine (RET 10 μM; purple bar). * indicates values significantly different (p < 0.05) from respective control. (C) HPLC traces of retigabine (RET) and compound 60 at 550 nm after 3 h exposure to UV–visible light.CC BY · PubMed Central
Figure 4 Effect of retigabine (RET), RL-81, and compound 60 on Kv7.2/Kv7.3 currents. (A) Representative macroscopic current traces recorded from CHO cell expressing Kv7.2/Kv7.3 channels in response to the indicated voltage protocol before (left) and after (right) application of 1 μM RET, RL-81 and compound 60, as indicated. Current scale, 200 pA; time scale, 200 ms. (B,C) Dose–response curves reporting the effects of the 3 indicated compounds on the V1/2 shift (ΔV1/2) in mV (B) and on maximal current density (Idrug/Icontrol; C) calculated at +20 mV for Kv7.2/Kv7.3 channels. (D,E) Current density of the indicated homomeric Kv7.2 channels (D) and the effect of 10 μM RET or 1 μM 60 on the indicated homomeric Kv7.2 mutant channels. * indicates values significantly different (p < 0.05) from respective controls.
Figure 4 Effect of retigabine (RET), RL-81, and compound 60 on Kv7.2/Kv7.3 currents. (A) Representative macroscopic current traces recorded from CHO cell expressing Kv7.2/Kv7.3 channels in response to the indicated voltage protocol before (left) and after (right) application of 1 μM RET, RL-81 and compound 60, as indicated. Current scale, 200 pA; time scale, 200 ms. (B,C) Dose–response curves reporting the effects of the 3 indicated compounds on the V1/2 shift (ΔV1/2) in mV (B) and on maximal current density (Idrug/Icontrol; C) calculated at +20 mV for Kv7.2/Kv7.3 channels. (D,E) Current density of the indicated homomeric Kv7.2 channels (D) and the effect of 10 μM RET or 1 μM 60 on the indicated homomeric Kv7.2 mutant channels. * indicates values significantly different (p < 0.05) from respective controls.CC BY · PubMed Central
Figure 5 Anticonvulsant efficacy of retigabine and compound 60 (c60) in pentylenetetrazol (PTZ)-induced acute seizures in mice. (A,B) Average values for the seizure score (A) and latency to onset of a maximal seizure (B) as a function of retigabine (RET) or compound 60 doses. Individual scores calculated in each animal are indicated by dots. (C,D) Effect of retigabine (RET) and compound 60, with (hatched bars) or without (empty bars) pretreatment with XE991 (XE 3 mg/kg) on seizure score (C) and latency to onset of a maximal seizure (D). (E) Effect of RET (1, 3 mg/kg), c60 (0.3–1 mg/kg) or XE991 (3 mg/kg) on mice survival rate after PTZ exposure. The number of animals used in each group was: 19 for controls, 4 for XE (3 mg/kg), 8 for RET (1 mg/kg), 10 for RET (3 mg/kg), 8 for XE + RET (3 + 1 mg/kg); 3 for c60 (0.1 mg/kg), 15 for c60 (0.3 mg/kg), 8 for c60 (1 mg/kg), and 8 for XE + c60 (3 + 0.1 mg/kg). The asterisk (*) indicates values significantly different (p < 0.05) from respective controls.
Figure 5 Anticonvulsant efficacy of retigabine and compound 60 (c60) in pentylenetetrazol (PTZ)-induced acute seizures in mice. (A,B) Average values for the seizure score (A) and latency to onset of a maximal seizure (B) as a function of retigabine (RET) or compound 60 doses. Individual scores calculated in each animal are indicated by dots. (C,D) Effect of retigabine (RET) and compound 60, with (hatched bars) or without (empty bars) pretreatment with XE991 (XE 3 mg/kg) on seizure score (C) and latency to onset of a maximal seizure (D). (E) Effect of RET (1, 3 mg/kg), c60 (0.3–1 mg/kg) or XE991 (3 mg/kg) on mice survival rate after PTZ exposure. The number of animals used in each group was: 19 for controls, 4 for XE (3 mg/kg), 8 for RET (1 mg/kg), 10 for RET (3 mg/kg), 8 for XE + RET (3 + 1 mg/kg); 3 for c60 (0.1 mg/kg), 15 for c60 (0.3 mg/kg), 8 for c60 (1 mg/kg), and 8 for XE + c60 (3 + 0.1 mg/kg). The asterisk (*) indicates values significantly different (p < 0.05) from respective controls.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 6

  1. Zaczek R., 1998, J. Pharmacol. Exp. Ther., 285, 724
  2. 2020, Schrödinger Release 2020–1: Maestro
  3. 2020, Schrödinger Release 2020–1: LigPrep
  4. 2020, Schrödinger Release 2020–1: Glide
  5. 2019, Schrödinger Release 2019–1: Desmond Molecular Dynamics System
  6. 2019, Maestro-Desmond Interoperability Tools

Cited by

See all 46

Metadata

Authors
Musella, S., Carotenuto, L., Iraci, N., Baroli, G., Ciaglia, T., Nappi, P., Basilicata, M. G., Salviati, E., Barrese, V., Vestuto, V., Pignataro, G., Pepe, G., Sommella, E., Di Sarno, V., Manfra, M., Campiglia, P., Gomez-Monterrey, I., Bertamino, A., Taglialatela, M., Ostacolo, C., & Miceli, F.
Affiliations
  • University of Salerno (IT)
  • University of Naples Federico II (IT)
  • University of Messina (IT)
  • Department of Pharmacy, University of Salerno, Via G. Paolo II 132, Fisciano 84084, Salerno, Italy
  • University of Basilicata (IT)
Corresponding author
  • Taglialatela, Maurizio
  • Ostacolo, Carmine
Venue
Journal of Medicinal Chemistry
Published
2022-08-16
Volume
65
Issue
16
Pages
11340-11364
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4292004335
Cited by
45
References
61
Citations by year
2026: 14 · 2025: 11 · 2024: 13 · 2023: 4 · 2022: 3
FWCI
2.53
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Basilicata) (submittedVersion, public-domain)
Funders
  • Ministero dell?Istruzione, dell?Universit? e della Ricerca (PRIN 2017ALCR7C, PRIN 2017YH3SXK, PRIN 2020L45ZW4)
  • Universit? degli Studi di Napoli Federico II
  • Compagnia di San Paolo
  • Ministero della Salute (RF-2019-12370491)
  • H2020 Health (825575, 875299)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
Kv7 channels, antiepileptic drugs, epilepsy, structure-activity relationship, retigabine, elimination half-life, photostability, Kv7.2
MeSH terms
Animals, Anticonvulsants, Carbamates, Phenylenediamines, Seizures, Mice, KCNQ2 Potassium Channel, KCNQ3 Potassium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c00911
The paper
Musella, S., Carotenuto, L., Iraci, N., Baroli, G., Ciaglia, T., Nappi, P., Basilicata, M. G., Salviati, E., Barrese, V., Vestuto, V., Pignataro, G., Pepe, G., Sommella, E., Di Sarno, V., Manfra, M., Campiglia, P., Gomez-Monterrey, I., Bertamino, A., Taglialatela, M., . . . Miceli, F. (2022). Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c00911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.